P rimary percutaneous coronary intervention (PCI) with immediate stenting (IS) is the current standard of reperfusion strategy for ST-segment-elevation myocardial infarction (STEMI). 1,2 However, it is thought that IS may cause additional myocardial injury by increasing distal embolization of clot and atheromatous plaque debris. Only ≈35% of patients without cardiogenic shock can achieve optimal myocardial tissue perfusion at the microvascular level, even after restoration of epicardial coronary artery patency. 3 This condition with hypoperfusion of the microvascular bed is called a myocardial noreflow and is produced by microvascular obstruction (MVO). 4
Immediate Versus Deferred Stenting in Primary PCI
increased myocardial salvage assessed by cardiac magnetic resonance (CMR) imaging in STEMI patients. 6 Gadoliniumenhanced CMR provides a comprehensive and quantitative analysis with high resolution of both the infarct and MVO, which are the 2 most important prognostic factors for left ventricular remodeling and mortality in STEMI patients who have undergone primary PCI. [7] [8] [9] Therefore, we aimed to assess that DS strategy to reduce both infarct size and MVO as assessed by CMR, compared to IS in primary PCI for STEMI.
Methods

Study Design and Patient Population
The INNOVATION trial (Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-Segment-Elevation Myocardial Infarction) is a 2-center, prospective, randomized, controlled, openlabel clinical trial for STEMI patients. This study was approved by the institutional review board at 2 centers. Patients were eligible for enrollment if the following criteria were met: (1) ≥18 years of age;
(2) >30 minutes in duration of typical chest pain; (3) ≥1 mm of STelevation on ≥2 contiguous leads; (4) duration of ischemic symptoms of <12 hours; (5) TIMI (Thrombolysis in Myocardial Infarction) flow 0, 1, or 2 before the procedure; and (6) achievement of TIMI 3 flow after balloon angioplasty or thrombus aspiration. Exclusion criteria were the following: (1) cardiogenic shock, (2) history of myocardial infarction (MI) or coronary artery bypass surgery, (3) rescue PCI after fibrinolysis, (4) life expectancy of <1 year, (5) acute occlusion of left main coronary artery, (6) contraindication to CMR imaging, (7) STEMI because of stent thrombosis, and (8) major coronary dissection (type D-F) after procedures achieving TIMI 3 flow. All eligible patients signed informed, written consent for study participation.
Randomization and Study Procedures
Eligible patients were randomly assigned to the IS group or DS group in a 1:1 ratio after achievement of TIMI 3 flow before stent implantation. Block randomization was performed with the block size of 2 and stratified by the site of participating center and the location of IRA (left anterior descending artery versus non-left anterior descending) by an interactive web-based system.
All patients received aspirin 300 mg and a loading dose of P2Y12 receptor inhibitor (clopidogrel 600 mg, ticagrelor 180 mg, or prasugrel 60 mg) before primary PCI. The selection of thienopyridine was left to the operator's discretion. The choice of transradial or transfemoral approach was also determined by the operator. The intravenous bolus of unfractionated heparin (100 U/kg) was administered to achieve therapeutic activated clotting time. The infusion of intracoronary abciximab (0.25 mg/kg) was highly recommended to most patients without contraindication of glycoprotein IIb/IIIa receptor block after guidewire had passed through the culprit lesion. Subsequent procedures included thrombus aspiration and balloon angioplasty. We classified thrombus amount into 5 grades by TIMI thrombus grading system and defined high thrombus burden as TIMI thrombus grade 4 and 5. 10 In the DS group, the second-stage stenting procedure was scheduled to be performed at 3 to 7 days after primary reperfusion procedure. Adjuvant antithrombotic therapy included infusion of intravenous abciximab (0.125 μg/kg/min for 12 hours) and unfractionated or low-molecular-weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) in both groups, and the decision of adjuvant antithrombotic use was dependent on the operator's discretion according to their bleeding risk. In case of minimal, residual plaque burden on angiogram or intravascular ultrasound during the second procedure, withdrawal of stent implantation was allowed in DS group. If patients with concurrent STEMI and multivessel disease underwent primary PCI, intervention of non-IRA was deferred in both groups. All stents used were drug-eluting stents including the Nobori Biolimus A9-eluting stent (Terumo, Tokyo, Japan) and Xience Prime everolimus-eluting stent (Abbott, IL). Dual antiplatelet therapy was maintained for ≈12 months. β-Blockers, angiotensin-converting enzyme inhibitors, and statins were given to patients according to current medical guidelines. High-intensity statin was highly recommended before or after primary reperfusion procedure in all eligible patients.
Study End Points
The primary end point was infarct size (percent of total left ventricular mass) measured by CMR at 30 days after primary reperfusion procedure. The major secondary end points were the incidence and size of MVO and the MVO to infarct ratio. Additional secondary end points included the peak value of serum creatine kinase-myocardial band (CK-MB), rate of complete ST-segment resolution on ECG assessed 60 minutes after primary reperfusion, corrected TIMI frame count, myocardial brush grade (MBG), TIMI myocardial perfusion grade (TMPG), and rate of no-reflow or slow flow phenomenon (TIMI flow grade 0-2). Definitions of secondary and safety end points were summarized in the Data Supplement. All angiographic and electrocardiographic data were analyzed at core laboratory (Sejong General Hospital, Bucheon, Korea).
Contrast CMR Imaging Protocols and Analysis
CMR imaging was performed using a 1.5-T whole-body scanner (see the Data Supplement). Infarct tissue was defined as an area of hyperenhancement on late gadolinium enhancement images. MVO was defined as an area of hypoenhancement within the hyper-enhanced infarct tissue. 11 Quantitative core laboratory measurements for infarct and MVO sizes were performed by a cardiac radiologist specializing in CMR imaging in Sejong general hospital, who was blinded to random assignment.
Statistical Analysis
We used intention-to-treat principle to analyze the primary and secondary outcomes. We assumed a myocardial infarct size after IS as 18±10% based on previous large CMR studies and expected a relative reduction of 30% by DS strategy. 11, 12 Considering a 5% of attrition rate because of follow-up loss and inadequate CMR, we estimated that 114 patients would be required for randomization to validate the difference with a statistical power of 80% and an α value of 0.05 with 2-sided t test. We also performed prespecified subgroup analysis for anterior versus nonanterior wall MI, because it is a most powerful clinical factor that affects infarct size and the incidence of MVO. We analyzed missing data with multiple imputation procedure. It was based on 10 data sets that have been imputed using a Markov chain Monte Carlo method, and the comparison between 2 groups was analyzed using the average of the estimates from 10 imputed data sets. We used general linear mixed model to control for the impact of random stratification factors on infarct size and the incidence of MVO. All statistical analyses were performed with the Statistical Package for Social Sciences (SPSS version 15; SPSS, Chicago, IL).
WHAT IS KNOWN
• Immediate stenting in highly thrombotic and inflammatory milieu within an infarct-related artery can cause additional myocardial injury by increasing distal embolization of clot and atheromatous plaque debris in ST-segment-elevation myocardial infarction.
WHAT THE STUDY ADDS
• A routine deferred stenting did not significantly reduce infarct size and microvascular obstruction, although it was safe.
Results
Study Population and Treatment
From February 2013 through March 2015, a total of 304 patients were screened for enrollment in this study ( Figure 1 ). Of these patients, 114 patients (37.5%) were enrolled and randomly assigned to either the DS group (n=57) or the IS group (n=57). Six patients in the DS group was crossed over into the IS group because of the progression of dissection or fear of such progression after randomization. One patient in the IS group was crossed over into the DS group according to operator's decision. Two patients withdrew consent during followup, and 5 patients did not undergo CMR for various reasons (claustrophobia, uncontrolled arrhythmia, poor general condition, and inadequate breath holding). Finally, 104 patients were included in the CMR analysis after excluding 1 patient whose imaging was inadequate for analysis of infarct size.
Baseline demographic and clinical characteristics of patients were well balanced between the 2 groups except for hypertension (31.6% versus 63.2% for IS versus DS group, respectively; P=0.001; Table 1 ). Baseline angiographic and procedure characteristics are shown in Table 2 . The left anterior descending artery was most frequently involved among IRA in both groups. The proportion of a high thrombi burden was relatively high and similar between 2 groups (87.7% of total). The interval from symptom onset to TIMI 3 flow was longer in the IS group compared with DS group (222 versus 175 minutes; P=0.046). It took 72 hours on average between primary reperfusion procedure and stent implantation in the DS group. Treatment strategies to achieve TIMI 3 flow were not significantly different between the 2 groups. Adjuvant infusion of intravenous abciximab after primary reperfusion was also similar between the 2 groups. Four patients (7%) in the DS group did not undergo stent implantation according to the operator's discretion. The stent diameter was significantly larger in the DS group than that in the IS group (3.1±0.4 versus 3.4±0.4 mm; P=0.011). Length of hospital stay was longer in the DS group compared with that in the IS group (median, 98 hours [interquartile range, 29-146] versus 121 hours [interquartile range, 97-151]; P=0.011), but length of intensive care unit stay did not differ significantly between 2 groups (median, 29 hours [interquartile range, 22-45] versus 33 hours [interquartile range, 24-63]; P=0.168; Table 1 ).
Efficacy End Points
The intention-to-treat analysis showed that the infarct size and the incidence of MVO were not significantly different between the IS and DS groups (19.4±12.0% versus 15.0±9.8%; P=0.112 for infarct size and 57.4% versus 42.6%; P=0.196 for MVO incidence). The size of MVO was also not significantly different between the 2 groups (0.6±0.7% versus 0.4±0.6%; P=0.156). Only the ratio of MVO to infarct was significantly smaller in the DS group (2.6±3.0% versus 1.4±1.9%; P=0.027; Table 3 ). As-treated analysis showed a similar result to the intention-to-treat analysis. The rate of complete ST resolution was not different between the 2 groups (36.8% versus 44.6%; P=0.677). The peak level of CK-MB was higher in the IS group (260±173 versus 199±136 ng/mL; P=0.046). However, The CK-MB area under the curve was not significantly different between the 2 groups (2775±1797 versus 2330±1589 ng/ mL; P=0.189). The rates of MBG 3 and TMPG 3 was significantly higher in the DS group (49.1% versus 68.4%; P=0.038 for MBG and 31.6% versus 49.1%; P=0.020 for TMPG, respectively). The incidence of slow or no-reflow was not significantly different (35.1% versus 22.8%; P=0.139; Table 4 ). Subgroup analysis of patients with anterior wall infarction showed significant differences between 2 groups in terms of primary and secondary end points. Infarct size was significantly smaller (22.7±12.7 versus 16.1±10.4%; P=0.017), and the incidence of MVO was significantly lower in the DS group (70.3% versus 43.8%; P=0.047). The size of MVO was tended to be smaller (0.7±0.7 versus 0.4±0.6%; P=0.06), and the ratio of MVO to infarct was significantly smaller in DS group (2.8±2.6 versus 1.4±1.9%; P=0.031; Table 3 ). The rate of MBG 3 and TMPG 3 were significantly higher in the DS group (43.2% versus 75%; P=0.01 for MBG 3 and 37.8% versus 71.9%; P=0.006 for TMPG 3, respectively; Table 4 ).
In the as-treated analysis, differences between the 2 groups were similar to intention-to-treat analysis in patients with anterior infarction in terms of CMR parameters, favoring the DS strategy (infarct size: 22.7±12.6% versus 15±10.4%; P=0.010 and MVO incidence: 68.6% versus 37.0%; P=0. 015).
Safety End Points
There was no event of urgent revascularization after primary reperfusion procedure in the DS group. There were no TIMI major bleeding events during in-hospital periods in either group. We analyzed angiographic findings of the 51 patients, actually treated with the DS strategy to assess the safety of DS. Comparisons with final angiogram of the primary reperfusion procedure showed that progression of residual stenosis >10% was found in only 2 of the 51 DS-treated patients (3.9%), and progression of dissection occurred also in only 2 of the 51 DStreated patients (3.9%; Figure 2A and 2B). Coronary angiograms of the second procedure showed significantly reduced thrombus burden when compared with the final angiogram of the primary reperfusion procedures ( Figure 2C ). There was no access site complication associated with repeated punctures or different puncture sites in the DS group.
Discussion
The major findings of this prospective randomized study in patients with STEMI undergoing primary PCI are as follows: (1) deferral of stent implantation during primary PCI did not significantly reduce infarct size and the incidence of MVO 30 days after STEMI; (2) in patients with anterior wall MI, DS significantly reduced infarct size and the incidence of MVO; and (3) there was neither urgent revascularization nor TIMI major bleeding during the deferral interval in the DS group.
We hypothesized that a substantial portion of MVO is initiated at the time of stent implantation during primary PCI, and this serious problem can be effectively prevented by deferring the implantation of a stent, without any increase in adverse events. The efficacy of DS strategy has been raised from 2 major theoretical bases. First, prolonged antiplatelet therapy and anticoagulation for a deferral period enabled the resolution of thrombus burden in IRAs, which is a substrate of distal embolization and subsequent MVO. Actually, when we compared angiographic findings with regard to thrombus burden between first and second procedures in the DS group, we found that thrombi in the culprit artery had decreased or completely disappeared in all of the 51 DS-treated patients.
Second rationale is what is called the vascular cooling down to avoid mechanical stimulus in the milieu of active inflammation within an IRA in the early phases of MI and prolong exposure to intensive statin therapy before stent implantation. Inflammation is known to be related to MVO and myocardial injury in STEMI. [13] [14] [15] Intensive statin therapy has been reported to exert anti-inflammatory and platelet inhibitory actions in these patients. 16 Accordingly, stent implantation after vascular cooling down period might minimize the effect of inflammation on myocardial damage. In our study, the administration of high-dose statin was highly encouraged to all enrolled patients at initial presentation according to study protocol. Despite these promising theoretical backgrounds, in this study, the infarct size and incidence of MVO were not significantly reduced compared with IS group, after deferral of stent implantation for 72 hours. Our study do not support routine deferral of stent implantation to mitigate or prevent myocardial no-reflow in STEMI patients. This result is inconsistent with a recently published DEFER-STEMI study (Deferred Stent Trial in STEMI). 6 This proof-of-concept study demonstrated that the DS with intention to stent after 4 to 16 hours reduces angiographic no-reflow phenomenon in STEMI patients. For the negative result of our study, even though longer deferred interval to reduce thrombus burden and inflammation compared with DEFER-STEMI study, we should take into considerations the differences of methodology to estimate myocardial no-reflow and a possibility of ethnic variation in terms of efficacy of DS. In patients with anterior wall MI, DS significantly reduce infarct size and MVO by 29.1% and 37.7%, respectively, compared with IS in this study. However, this study did not initially incorporate subgroups in the power analysis to estimate sample size, and the differences shown in the subgroup analysis should not be considered conclusive. A culprit lesion in left anterior descending with large territory may be more susceptible to distal embolization because it has a larger microvascular bed, compared with right coronary or left circumflex artery. We speculate that DS can be beneficial to reduce infarct size and myocardial no-reflow in patients who have large MVOprone conditions, such as large amount of thrombus burden, and large microvascular bed. Accordingly, in which patients deferred stenting is beneficial should be delineated in a larger In our study, DS with intention to stent after 3 to 7 days was performed after 3 days on average, after primary procedure. Our study suggests that deferral of stent implantation for several days can be safely performed. No major bleeding event occurred in the DS group, despite the longer duration of anticoagulation. Regarding other safety issues, only 2 patients experienced >10% progression of residual stenosis, and none had flow-limiting progression of dissection between the first and second procedures among 51 DS-treated patients. These findings were linked to no event of urgent revascularization during the deferral interval in the DS group.
Coronary angiogram has several limitations in terms of comparing myocardial no-reflow between 2 groups. We evaluated MBG and TMPG and corrected TIMI frame counts at the end of the primary reperfusion procedure. At that time, the DS group had a mean of 55% residual stenosis, about half of them had a coronary dissection, and >70% had a floating thrombus in culprit vessels. Moreover, the incidence of no-reflow or slow flow was evaluated at any time during the first and second procedures in the DS group, in contrast to the IS group. Therefore, we could not fairly compare angiographic secondary end points between the 2 groups. To overcome the inability to compare the angiographic outcomes between the 2 groups, we assessed infarct size and MVO by CMR as primary and secondary end points. CMR facilitates visualization of infarct size and the presence and size of MVO with high accuracy and reproducibility. Especially, MVO as evaluated by CMR was the best predictor of global functional recovery, 17 major adverse cardiac events, and long-term cardiac mortality in STEMI patients. 11 Our study had a strength in that the preventive effect of DS against MVO was evaluated using a more reliable surrogate end point. CMR was checked at 30 days after primary perfusion for assessment of infarct size and MVO, because ≥1 weeks are required to resolve infarct tissue edema and the functional component of MVO.
We experienced 1 patient of major dissection before randomization and excluded this case. Six patients who were randomized into DS after achieving TIMI 3 flow without There was no significant difference between 2 angiographic findings for each type of coronary dissection (P value=0.414, 0.317, and 0.157 for type A, B, and C, respectively). C, Comparison of TIMI (Thrombolysis in Myocardial Infarction) thrombus grade between initial angiogram in primary reperfusion procedure and initial angiogram in second-stage procedure. major dissection during the initial procedure were crossed over to the IS group. Among them, 4 patients with old age and calcified lesion lately developed progressive dissection or reocclusion and 2 patients were crossed over to the IS group because of fear of reocclusion, according to physician's discretion. Therefore, we should carefully monitor late progression of dissection or reocclusion during the initial procedure in DS strategy even though our data showed that there was no urgent ischemia-driven PCI during the deferral interval. This explains the poor enrollment of study population according to physician's preference, and this is consistent with DEFER-STEMI trial. 6 However, considering no significant change was observed in residual stenosis and dissection and improved thrombus grade in follow-up angiography, DS could be performed without additional risk of adverse events with meticulous monitoring during the initial procedure.
We found that some patients assigned to DS group finally underwent successful recanalization without stenting. This result is consistent with previously published data. 6, 18 Some patients with STEMI has minimal plaque burden, with or without plaque rupture. Using a DS strategy can allow patients that don't need stent implantation after thrombus resolution to be detected.
Study Limitations
Our study has several limitations. First, sample size was relatively modest for proving the efficacy end point and to evaluate the impact of DS on clinical outcomes. Second, investigators and patients were unblinded. To overcome this limitation, electrocardiographic and angiographic analysis and CMR measurements were performed by core laboratory staff, blinded to random assignment. Third, as shown in the patient flowchart, many interventional cardiologists did not prefer to enroll of patients because they worried about the risk of acute reocclusion or urgent revascularization in the DS group. This could be a potential source of selection bias in patient enrollment. Also, when readers interpret the result of our study, they should take into considerations that our study was 2-centered, enrolled many patients with male sex, anterior MI than previous studies, and assessed major end points in survivor population. Third, the prevalence of hypertension and the symptom to TIMI 3 flow time were different between the both group, and we think it may be because of chance according to randomization, but we cannot rule out the possibility to affect the outcomes. Fourth, we need a large study population for safety issues, especially urgent revascularization during deferral interval although our study proved relative safety of DS treatment. Fifth, cost of DS could be an issue because of healthcare policy and financing. In spite of this, the potential benefit of DS in respect to increased myocardial salvage should be discussed.
Conclusions
Routine deferral of stent implantation to prevent distal embolization of thrombus, and atherosclerotic debris did not significantly reduce infarct size and myocardial no-reflow compared with IS in all STEMI patients, although it was safe in this small study. In which patients DS is beneficial should be evaluated in larger randomized controlled trials.
